China
Africa
Explore chapters and articles related to this topic
Emerging Potential of In Vitro Diagnostic Devices: Applications and Current Status
Published in Debarshi Kar Mahapatra, Sanjay Kumar Bharti, Medicinal Chemistry with Pharmaceutical Product Development, 2019
Swarnali Das Paul, Gunjan Jeswani
In 2013, Abbott introduced a new glucose monitoring technology called “Flash Glucose Monitoring.” It was designed to collect continuous glucose data to permit generation of an innovative report by software called the “Ambulatory Glucose Profile.” This technology was a good alternative to conventional glucose test instead of using traditional finger-sticks. Table 9.6 represents information on differently recently approved glucose monitoring devices for home use by FDA.
How use of continuous glucose monitoring can address therapeutic inertia in primary care
Published in Postgraduate Medicine, 2022
Thomas W. Martens, Christopher G. Parkin
Prior to the development of CGM data upload programs, many clinicians were overwhelmed by the vast amount of data collected by CGM. As such, using downloaded CGM data in many clinical settings was hindered by a number of factors, including time constraints, reimbursement issues, clinician inexperience with data interpretation, and lack of standardized reports [75]. In 2013, an expert panel developed recommendations for using the Ambulatory Glucose Profile (AGP) as a template for presenting CGM data in a standardized report [76]. The Ambulatory Glucose Profile (AGP) aggregates data from a CGM device via cloud-based transmission or download from a reader/receiver and displays the data in an easy to interpret report based on the established CGM metrics [74,77]. Initially proposed by Mazze et al. in 1987 [78] and subsequently enhanced by input from the International Diabetes Center and various diabetes consensus groups [74,77], the AGP report components have been incorporated into the various product-specific software programs by CGM manufacturers, allowing a consistent visualization format for both clinicians and patients.
Continuous glucose monitoring in persons with type 2 diabetes not using insulin
Published in Expert Review of Medical Devices, 2021
Kevin Cowart, Wendy H. Updike, Rachel Franks
CGM allows the PWD and clinician to analyze the impact that diet, exercise, stress, and medication can have on the management of T2D[10]. CGM can be used to monitor additional glycemic metrics beyond HbA1c and SMBG, such as time in range (TIR), time above range (TAR), time below range (TBR), glycemic variability (GV), mean glucose, and glucose management indicator (GMI), which is used to estimate the HbA1c from a CGM sensor wear period[8]. These metrics are available for the clinician to review in the form of a report called the ambulatory glucose profile following a sensor wear period[10]. Together, these metrics provide a more comprehensive assessment of glycemic control[8]. Several of these metrics, such as the TIR, and GV, are associated with development of diabetes complications [14–16]. CGM devices are currently available as either rtCGM or FGM, with both devices measuring interstitial glucose, with options for glucose measurements to be either blinded or un-blinded to the PWD.
Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C)
Published in Postgraduate Medicine, 2021
Thomas W Martens, Richard M Bergenstal, Teresa Pearson, Anders L Carlson, Gary Scheiner, Campos Carlos, Birong Liao, Kristen Syring, Roy Daniel Pollom
Promising therapies for the management of diabetes have emerged in the last 20 years, yet improved outcomes have been slow to follow [4,5]. Many factors have impacted the ability to optimize diabetes management, including issues of cost of care and access to care globally and nationally, and suboptimal therapeutic intensification or titration on an individual level. In fact, nationally we are seeing a resurgence in diabetes-related complications [6]. Continuous glucose monitoring (CGM) technology as well as retrospective pattern-based management using CGM reporting tools such as the Ambulatory Glucose Profile (AGP) have the potential to dramatically improve glycemic management. Strategies to optimally use CGM data to improve the care of persons with diabetes (PwD) will be discussed.